Weight-Loss Drugs and Hair Loss: New Genetic Evidence

A recent study reveals potential side effects of popular weight-loss drugs beyond their primary purpose. Researchers at NYU Langone Health found that medications like Ozempic, Wegovy, and Zepbound could increase hair loss risk in men predisposed to male-pattern baldness.

Link Between GLP-1 Drugs and Hair Loss

The findings, published on September 3 in the Journal of Investigative Dermatology, present the first genetic evidence of GLP-1 activity linked to androgenetic alopecia. This common form of hair loss affects many men.

Dr. Ahmed El Muntasar, a General Practitioner uninvolved in the study, explained to Newsweek that rapid weight loss and nutrient deficiencies can lead to temporary hair shedding. For individuals with a genetic tendency for male-pattern hair loss, GLP-1 receptor activity might exacerbate the condition.

Diabetes and Medication Use

The Centers for Disease Control and Prevention (CDC) reports that over 25% of adults with diagnosed diabetes used GLP-1 injectables in 2024. The rate of usage was nearly equal for men and women.

Findings from the Study

According to Lynn Petukhova, a senior investigator of the study, this research provides the first genetic link between GLP-1 usage and increased risk of male-pattern hair loss. The study observed a 7% heightened risk associated with these medications.

The researchers explored the GLP1R gene, which raises GLP-1 receptor protein levels, and compared genetic markers for increased GLP-1 activity with those linked to androgenetic alopecia. This comparison aimed to verify a causal relationship.

Beyond Weight Loss

Hair thinning frequently occurs with GLP-1 medication intake, often attributed to rapid weight loss. Many regain hair growth after weight stabilization. However, the study suggests a biological link beyond mere weight loss.

Adjusting for factors like hypertension, insulin resistance, and testosterone levels, the 7% increased risk persisted. The research analyzed genetic data from over 31,000 men and women in the eQTLGen database and more than 205,000 men in another dataset.

Implications for Patients

Given the genetic overlap, Petukhova suggests that future experiments might allow screening for hair loss risk before prescribing GLP-1 medications. El Muntasar advises against panic, stressing that a 7% increase is modest and the research provides a biological indication rather than conclusive proof.

Petukhova highlights the potential for preventative strategies, like prescribing hair loss-reducing medications alongside GLP-1 therapies. However, more studies are needed to explore GLP-1 pathways’ effects on hair follicles and the application to women.

Androgenetic alopecia affects approximately 50% of white American men over 50. As GLP-1 drugs gain popularity, recognizing side effects and identifying at-risk individuals will be crucial.